About: Connectivity guided theta burst transcranial magnetic stimulation versus repetitive transcranial magnetic stimulation for treatment-resistant moderate to severe depression: study protocol for a randomised double-blind controlled trial (BRIGhTMIND)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Connectivity guided theta burst transcranial magnetic stimulation versus repetitive transcranial magnetic stimulation for treatment-resistant moderate to severe depression: study protocol for a randomised double-blind controlled trial (BRIGhTMIND) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Connectivity guided theta burst transcranial magnetic stimulation versus repetitive transcranial magnetic stimulation for treatment-resistant moderate to severe depression: study protocol for a randomised double-blind controlled trial (BRIGhTMIND)
Source	PMC
abstract	INTRODUCTION: The BRIGhTMIND study aims to determine the clinical effectiveness, cost-effectiveness and mechanism of action of connectivity guided intermittent theta burst stimulation (cgiTBS) versus standard repetitive transcranial magnetic stimulation (rTMS) in adults with moderate to severe treatment resistant depression. METHODS AND ANALYSIS: The study is a randomised double-blind controlled trial with 1:1 allocation to either 20 sessions of (1) cgiTBS or (2) neuronavigated rTMS not using connectivity guidance. A total of 368 eligible participants with a diagnosis of current unipolar major depressive disorder that is both treatment resistant (defined as scoring 2 or more on the Massachusetts General Hospital Staging Score) and moderate to severe (scoring >16 on the 17-item Hamilton Depression Rating Scale (HDRS-17)), will be recruited from primary and secondary care settings at four treatment centres in the UK. The primary outcome is depression response at 16 weeks (50% or greater reduction in HDRS-17 score from baseline). Secondary outcomes include assessments of self-rated depression, anxiety, psychosocial functioning, cognition and quality of life at 8, 16 and 26 weeks postrandomisation. Cost-effectiveness, patient acceptability, safety, mechanism of action and predictors of response will also be examined. ETHICS AND DISSEMINATION: Ethical approval was granted by East Midlands Leicester Central Research Ethics Committee (ref: 18/EM/0232) on 30 August 2018. The results of the study will be published in relevant peer-reviewed journals, and then through professional and public conferences and media. Further publications will explore patient experience, moderators and mediators of outcome and mechanism of action. TRIAL REGISTRATION NUMBER: ISRCTN19674644
has issue date	2020-07-07(xsd:dateTime)
bibo:doi	10.1136/bmjopen-2020-038430
has license	cc-by
sha1sum (hex)	4c5ec7bfde0977884a8eed37b0ba4cda21ebfcc9
schema:url	https://doi.org/10.1136/bmjopen-2020-038430
resource representing a document's title	Connectivity guided theta burst transcranial magnetic stimulation versus repetitive transcranial magnetic stimulation for treatment-resistant moderate to severe depression: study protocol for a randomised double-blind controlled trial (BRIGhTMIND)
has PubMed Central identifier	PMC7342821
schema:publication	BMJ Open
resource representing a document's body	covid:4c5ec7bfde0977884a8eed37b0ba4cda21ebfcc9#body_text
is schema:about of	named entity 'Appendix' named entity 'DEGREE' named entity 'Appendix 1' named entity 'Psychopharmacology' named entity 'quetiapine' named entity 'methylphenidate' named entity 'minimum effective' named entity 'minimum effective dose' named entity 'response times' named entity 'vortioxetine' named entity 'ECT' named entity 'antidepressant' named entity 'antidepressant' named entity 'Summary of Product Characteristics' named entity 'aripiprazole' named entity 'psychostimulants' named entity 'depression' named entity 'electroconvulsive therapy' named entity 'rumination' named entity 'executive function' named entity 'moclobemide' named entity 'monoamine oxidase inhibitor' named entity 'Ritalin' named entity 'buspirone' named entity 'pramipexole' named entity 'antidepressant' named entity 'dosulepin' named entity 'reaction times' named entity 'depression' named entity 'low mood' named entity 'antidepressant' named entity 'tricyclic antidepressants' named entity 'RCT' named entity 'antidepressants' named entity 'RCT' named entity 'Mirtazapine' named entity 'modafinil' named entity 'clinical practice' named entity 'Depression' named entity 'amoxapine' named entity 'depression' named entity 'mirtazapine' named entity 'ADD' named entity 'TRD' named entity 'antidepressants' named entity 'Buspar' named entity 'positive correlation' named entity 'Zyprexa' named entity 'antidepressant' named entity 'secondary care' named entity 'mirtazapine' named entity 'risperidone' named entity 'episode of depression' named entity 'unblinded' named entity 'antidepressant' named entity 'olanzapine' named entity 'executive function' named entity 'fMRI' named entity 'time constant' named entity 'antidepressant' named entity 'antidepressant' named entity 'positive correlation' named entity 'atypical antipsychotics' named entity 'default mode network' named entity 'episode of depression' named entity 'unblinding' named entity 'antidepressant' named entity 'protriptyline' named entity 'episode of depression' named entity 'venlafaxine' named entity 'allocation group' named entity 'lithium' named entity 'mirtazapine' named entity 'agomelatine' named entity 'executive function' named entity 'ECT' named entity 'depression' named entity 'buspirone' named entity 'desipramine' named entity 'depression' named entity 'mis' named entity 'antidepressants' named entity 'psychotropics' named entity 'skewed distribution'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software